Gastroparesis Clinical Trial
Official title:
Pyloric Sphincter Pressure and Geometry Assessment Using EndoFlip
Gastroparesis is a disorder characterized by symptoms from gastric retention in the absence of mechanical obstruction. Gastric emptying is a highly regulated process reflecting the integration of the propulsive forces of proximal fundic tone and distal antral contractions with the functional resistance provided by the pyloric sphincter. Pylorospasm has been reported in some patients with gastroparesis. This study protocol will assess pyloric sphincter pressure and geometry in patients with gastroparesis and control subjects without symptoms of gastroparesis. The commercially available FDA approved endoscopic functional luminal imaging probe (EndoFLIP) catheter will be used, which measures diameter, pressure, length, and distensibility of gastrointestinal sphincter muscles along the balloon distance. It is used to measure the pressure characteristics of the lower esophageal sphincter during bariatric surgery for obesity, during Heller myotomy for achalasia, and during Nissen fundoplication for gastroesophageal reflux disease. In this study, during upper endoscopy, which is routinely performed under sedation, patients with gastroparesis and controls without gastroparesis symptoms will have their pyloric sphincter assessed with EndoFLIP. After passage of the endoscope into the stomach, the EndoFLIP catheter will be introduced alongside the endoscope and advanced through the pyloric sphincter as visualized endoscopically. The investigators will measure the pressure and contour of the pyloric sphincter using three successive volume distensions of the EndoFLIP balloon (20 ml, 30 ml, 40 ml). The investigators will compare the results between the gastroparesis patients and the control patients without gastroparesis. Through this study, the investigators will better understand the abnormalities of the pyloric sphincter in patients with gastroparesis.
This study protocol will assess pyloric sphincter pressure and geometry in patients with
gastroparesis and control subjects without symptoms of gastroparesis.
Aims: To determine if there is a subgroup of patients with gastroparesis who have pressure
and/or geometric configuration abnormalities of the pyloric sphincter. We will determine this
by assessing the pressure, diameter, length, and distensibility of the pyloric sphincter in
patients with gastroparesis and in subjects without gastroparesis undergoing upper endoscopy
for their clinical evaluation.
Hypothesis:The pylorus of patients with gastroparesis has a higher pressure, smaller
diameter, and is less distensible than the pylorus of control patients without gastroparesis
Methods: The commercially available FDA approved endoscopic functional luminal imaging probe
(EndoFLIP) catheter will be used, which measures diameter, pressure, length, and
distensibility of gastrointestinal sphincter muscles along the balloon distance. It is used
to measure the pressure characteristics of the lower esophageal sphincter during bariatric
surgery for obesity, during Heller myotomy for achalasia, and during Nissen fundoplication
for gastroesophageal reflux disease. In this study, during upper endoscopy, which is
routinely performed under sedation, patients with gastroparesis and controls without
gastroparesis symptoms will have their pyloric sphincter assessed with EndoFLIP. After
passage of the endoscope into the stomach, the EndoFLIP catheter will be introduced alongside
the endoscope and advanced through the pyloric sphincter as visualized endoscopically. The
investigators will measure the pressure and contour of the pyloric sphincter using three
successive volume distensions of the EndoFLIP balloon (20 ml, 30 ml, 40 ml). The assessment
of the pylorus will be done during the upper endoscopy which will take approximately 60
minutes. We will compare the pyloric pressure measurements in patients with gastroparesis to
the control patients. This is an observational study, with no intervention.
Analysis: The investigators will compare the results between the gastroparesis patients and
the control patients without gastroparesis.
Through this study, the investigators will better understand the abnormalities of the pyloric
sphincter in patients with gastroparesis.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03941288 -
Efficacy and Safety of Cannabidiol for Gastroparesis and Functional Dyspepsia
|
Phase 2 | |
Terminated |
NCT03285308 -
A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis 01
|
Phase 3 | |
Completed |
NCT00733551 -
Evaluation of the Safety, Tolerability and Pharmacokinetics of Repeat Oral Doses of GSK962040 Administered to Healthy Adult Subjects.
|
Phase 1 | |
Completed |
NCT01650714 -
Endoscopic Full Thickness Biopsy, Gastric Wall.
|
N/A | |
Completed |
NCT01452815 -
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
|
Phase 2 | |
Completed |
NCT01039974 -
GSK962040 Drug-drug Interaction Study With Ketoconazole
|
Phase 1 | |
Terminated |
NCT04844190 -
Use of EndoFLIP and Manometry Prior to G-POEM
|
N/A | |
Enrolling by invitation |
NCT06215547 -
Medtronic Enterra II Neurostimulator
|
N/A | |
Completed |
NCT04026997 -
A Phase 2 Study of CIN-102 in Adults With Idiopathic and Diabetic Gastroparesis
|
Phase 2 | |
Completed |
NCT00562848 -
A Study to Evaluate Safety, Side Effects, Muscle Activity and Speed of Gastric Emptying of GSK962040
|
Phase 1 | |
Enrolling by invitation |
NCT04207996 -
Vagus Nerve Response in Gastroparesis Patients
|
||
Completed |
NCT04607304 -
ABCA2 GIRMS Analytical Validation Clinical Performance Study
|
N/A | |
Recruiting |
NCT06068114 -
Gastric Pathophysiology in Diabetes
|
||
Completed |
NCT03259841 -
Ultrasound Assessment of Gastric Contents in Fasted Patient Undergoing Cholecystectomy
|
||
Active, not recruiting |
NCT04300127 -
Pioglitazone for Idiopathic Gastroparesis
|
Early Phase 1 | |
Recruiting |
NCT01696734 -
Domperidone in Treating Patients With Gastrointestinal Disorders
|
Phase 3 | |
Terminated |
NCT04635306 -
13C-Spirulina Nitrogen Content GEBT Study
|
N/A | |
Withdrawn |
NCT02420925 -
Effect of Celiac Plexus Block on Gastric Emptying and Symptoms Caused by Gastroparesis
|
N/A | |
Recruiting |
NCT00777439 -
Domperidone for Refractory Gastrointestinal Disorders
|
N/A | |
Terminated |
NCT00760461 -
Domperidone in Refractory Gastroparesis
|
Phase 2 |